Do You Have to Stop Ozempic Before Surgery?

Medically reviewed by a licensed healthcare professional. Last updated May 2026.

Key Takeaways

• The blanket seven-day-stop rule for GLP-1s before elective surgery was reversed by the most recent multi-society guidance. Most patients can now continue their medication.
• Endoscopy and colonoscopy are case-by-case. The 2024 AGA update moved endoscopy to an individualized approach; asymptomatic patients on standard fasting can often proceed without holding, though many GI practices still default to a 7-day hold for bowel-prep reasons.
• High-risk patients (severe GI symptoms, gastroparesis, highest-dose, recent dose escalation) need shared decision-making with the anesthesia team. Options include deferring the procedure, a 24-hour liquid diet, bedside gastric ultrasound, adjusted anesthetic technique, or a hold.
• Some surgery-center protocols have not caught up to the updated guidance. Bring it up at the pre-op call if your team defaults to a 7-day hold without asking about your symptoms or risk factors.
• A one-week hold rarely causes meaningful weight regain. Hunger comes back within a few days. Resume at the usual dose after the procedure.

I started looking into the "stop your GLP-1 before surgery" question because three patients in three different states told me the same story in two weeks. They had elective procedures scheduled. They had told their surgical teams they were on Wegovy or Ozempic. The anesthesiologist had pulled them aside and said, with the seriousness usually reserved for blood thinners, that they had to stop the medication a full week before surgery or risk a fatal aspiration. Two of them had cancelled the surgery rather than risk a week of food cravings while their weight loss was working. The third had stopped the medication, lost the appetite suppression on day four, and showed up to her colonoscopy with a stomach full of solid food anyway.

The thing is, the seven-day-stop rule those anesthesiologists were following has been substantially walked back. Five major medical societies got together and issued joint guidance saying that for most patients, stopping the GLP-1 before surgery is no longer recommended. You would not know this if you read the consent forms most surgery centers are handing out, which still cite the older ASA-only recommendation from a couple of years before. So if you are on a GLP-1 and have a procedure coming up, you need to know what changed and how to have the right conversation with your team.

What the old rule said and where it came from

The original guidance from the American Society of Anesthesiologists was a response to a wave of case reports describing aspiration events during anesthesia in patients on GLP-1 receptor agonists. The reasoning made sense at the time. GLP-1s slow gastric emptying. Slow emptying means there can be solid food in the stomach hours after a meal. Solid food in the stomach during anesthesia means risk of regurgitation. Regurgitation under sedation can be fatal.

The ASA recommended holding weekly GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) for seven days before elective surgery and holding daily GLP-1s (Saxenda, Victoza) for the day of the procedure. That guidance got picked up by every surgery center, written into every pre-op handout, and trained into anesthesiology residents. The seven-day stop became standard of care fast.

The problem with the original guidance is that it was based on case reports, not on a systematic review of aspiration rates in GLP-1 patients versus matched controls. When that review actually got done, the picture was different.

What the updated guidance changed

A multi-society task force (ASA, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and SAGES) released updated guidance that reversed the prior recommendation. The headline reversal: most patients on GLP-1s should continue their medication before elective surgery.

The new approach favors three risk-mitigation strategies over blanket discontinuation:

Holding the medication is now reserved for patients in the high-risk category, which the guidance defines specifically.

Who still needs extra precautions

The guidance is not a blanket "continue the GLP-1." It identifies a set of patients who need extra mitigation, with the specific mitigation chosen by the anesthesia team based on the situation. Holding the medication is one option among several, not the default:

• Severe GI symptoms. Active nausea, vomiting, abdominal pain, severe reflux, or constipation in the days before surgery. Options range from deferring the elective procedure until symptoms settle, to a 24-hour liquid diet, to bedside gastric ultrasound.
• Diabetic gastroparesis. Patients with confirmed gastroparesis from diabetes have baseline slow emptying that the GLP-1 may worsen. Bedside ultrasound and adjusted anesthetic technique are common; a hold is reasonable in shared decision-making.
• Highest-dose patients. Patients on the top approved dose (2.4 mg/week semaglutide, 15 mg/week tirzepatide) have the strongest gastric-emptying effect. The 24-hour liquid diet is specifically recommended; a hold can be added if symptoms are present.
• Recent dose escalation. Patients who stepped up to a new dose within the last four weeks. The gastric effect is highest right after a dose change, so deferring the elective procedure until the escalation phase passes is often the cleanest option.

For all four groups, the consistent thread is shared decision-making with the anesthesia team. A liquid diet is the most common mitigation; a hold is reserved for cases where other strategies are not enough.

Colonoscopy and endoscopy are case by case

This is where the picture is messier than the surgery side. The 2024 AGA rapid clinical update moved endoscopy to an individualized approach rather than a universal hold. The framework:

• Asymptomatic patients on a GLP-1 who follow standard fasting protocols can generally proceed without holding the medication.
• Symptomatic patients (nausea, abdominal distension, reflux) should consider extra precautions: a clear liquid diet the day before the procedure, bedside gastric ultrasound to check for retained contents, or a hold if neither is feasible.

That said, many GI practices still default to a 7-day hold of weekly GLP-1s before colonoscopy. The reason is not aspiration. It is bowel prep. GLP-1s slow gastric and intestinal transit, which can interfere with the laxative bowel prep colonoscopy requires. Studies of matched cohorts show meaningfully higher inadequate-prep rates in GLP-1 patients who do not hold (roughly 11 to 15 percent inadequate prep in GLP-1 patients versus 5 to 7 percent in matched controls per recent cohort data), which is a smaller gap than some early reports suggested but still clinically meaningful.

Practically, this means:

• For elective colonoscopy, ask the GI practice what their current protocol is. Some have moved to clear-liquid-diet-plus-no-hold; others still require the 7-day hold of weekly GLP-1s.
• Daily GLP-1s (Saxenda, Victoza) typically only need to be held the day of the procedure.
• Either way, follow the bowel prep instructions to the letter. That matters more than the medication question for prep quality.

How to have the conversation with your surgical team

Some surgery-center protocols and consent forms have not caught up to the updated guidance. They still cite the original ASA-only recommendation, which is what got built into pre-op workflows when it shipped. If you bring up the update, the conversation usually goes well. Anesthesiologists are evidence-driven and most welcome the new approach because it reduces case cancellations.

Three things to do at your pre-op call:

1. Tell the scheduler the exact medication, dose, and date of your last injection. Not "I am on Ozempic." Say "I am on semaglutide 1.0 mg weekly, last injection was Tuesday." This information determines the actual plan.
2. Ask whether the facility is following the multi-society perioperative GLP-1 guidance or the older ASA-only recommendation. Most schedulers will not know. They will refer you to the anesthesiologist. That is fine.
3. If you are not in a high-risk category, ask whether the 24-hour liquid diet protocol is available in lieu of the seven-day hold. Most centers can accommodate this. If the answer is "no, we always require seven days," that is the moment to ask whether the policy has been updated and to consider whether the procedure is urgent enough to follow an outdated protocol.

What happens if you have to hold

A week-long hold of a weekly GLP-1 is not catastrophic. Most patients notice the hunger return by day three or four. The medication is still present in the bloodstream for several days after the last dose because semaglutide and tirzepatide have long half-lives (about a week). Resumption after the procedure restores appetite suppression within five to seven days at the usual dose.

The bigger problem with a longer hold (two weeks or more) is appetite rebound. Patients who hold for longer than two weeks often see two to five pounds of regain, and the medication takes seven to ten days to suppress appetite again after restart. If your surgery is going to require a hold longer than two weeks (some major surgeries with delayed return to oral intake), talk to your prescriber about how to plan the restart.

The honest version of this conversation

The original seven-day rule made sense with the data the ASA had at the time. The updated multi-society guidance makes more sense with the data we have now. The problem is that pre-op systems are slow to update. If you are scheduled for an elective surgery and you are on a GLP-1, you may get advice that is years out of date. The right response is not to argue with your anesthesiologist. The right response is to ask, calmly, whether they are working from the multi-society update. Most will say yes, or will be glad to hear about it if they have not.

For colonoscopy, endoscopy, or surgery where the team decides extra precautions are warranted, follow whatever protocol the procedure facility uses. For everything else, the new guidance is meaningful patient relief and you should not have to fight to be allowed to follow it.

For more on GLP-1 side effects in the weeks before and after a procedure, see our GLP-1 side effects timeline and our nausea management guide. For finding a clinic that can adjust dose or schedule around procedures, our 90-second matching quiz is the fastest path.

Sources

1. American Society of Anesthesiologists, New Multi-Society GLP-1 Clinical Practice Guidance Released
2. Multi-society clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period, PMC
3. AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy
4. GLP-1 Receptor Agonists and Peri-Procedural Aspiration Risk, PMC
5. Cleveland Clinic Journal of Medicine, Should GLP-1 receptor agonists be withheld during the preoperative period?
6. Houston Methodist, Study Challenges Seven-Day Hold on GLP-1 Agonists Before Surgery
7. Wegovy Prescribing Information (Novo Nordisk)
8. Zepbound Prescribing Information (Eli Lilly)